October 25, 2020
Video
New data may evidence oral care as a therapeutic measure to reduce bacterial and viral spread.
October 24, 2020
Article
The hospital found just 2 cases in their first 12 weeks were borne in the facility. A study author provides insight.
An investigator shares detail into how the neutralizing, immune-signaling molecule may provide continued success against the virus.
October 23, 2020
Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.
The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224).
October 22, 2020
New data highlight the need for more antimicrobial stewardship adoption in emergency care settings.
In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.
October 21, 2020
New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.
Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.
In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.
